ZoetisCHIX:ZOED 65 EV-to-FCF is 17.14 as of Jul. 01, 2026, which is 66% below its 10-year median of 50.18. GuruFocus rates CHIX:ZOED with a GF Score™ of 65/100 and a GF Value™ of €179.46 (Significantly Undervalued). Among 560 Drug Manufacturers companies, Zoetis ranks better than 60% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zoetis's Enterprise Value is €32,862 Mil.
Zoetis's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €1,917 Mil. Therefore, Zoetis's EV-to-FCF for today is 17.14.
The historical rank and industry rank for Zoetis's EV-to-FCF or its related term are showing as below:
CHIX:ZOEd'
s EV-to-FCF Range Over the Past 10 Years
Min: 16.73 Med: 50.18 Max: 73.26
Current: 16.73
During the past 13 years, the highest EV-to-FCF of Zoetis was 73.26. The lowest was 16.73. And the median was 50.18.
CHIX:ZOEd's EV-to-FCF is ranked better than 60% of 560
companies
in the Drug Manufacturers industry
Industry Median: 20.52
vs CHIX:ZOEd: 16.73
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-01), Zoetis's stock price is €66.44.
Zoetis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €5.183. Therefore, Zoetis's PE Ratio (TTM) for today is 12.82.
Zoetis (CHIX:ZOEd) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zoetis's share price for today is €66.44.
Zoetis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.183.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zoetis EV-to-FCF Related Terms
Zoetis EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Zoetis's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ZOED vs UTHR, VTRS, NBIX: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Zoetis's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zoetis EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zoetis's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zoetis's EV-to-FCF falls into.
Zoetis's current Enterprise Value is €32,862 Mil.
Zoetis's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,917 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zoetis (CHIX:ZOED) has a EV-to-FCF of 17.14 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zoetis and its competitors. This is 66% below median its historical median of 50.18. Over the past decade, Zoetis' EV-to-FCF has ranged from 16.73 to 73.26. According to the industry distribution chart, Zoetis ranks #224 out of 560 companies in the Drug Manufacturers industry, placing it in the top 40%.
Is Zoetis' EV-to-FCF too high?
Zoetis' current EV-to-FCF of 17.14 is 66% below median its 10-year median of 50.18. Over the past 10 years, this metric has ranged from a low of 16.73 to a high of 73.26. The Drug Manufacturers industry median EV-to-FCF is 20.52. Zoetis' value of 17.14 is 16.5% below this industry median. Based on the distribution chart, Zoetis ranks #224 out of 560 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Zoetis has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zoetis' EV-to-FCF compare to UTHR and VTRS?
According to the Drug Manufacturers industry distribution chart, Zoetis ranks #224 out of 560 companies for EV-to-FCF. This puts Zoetis in the upper half of its industry. The industry median EV-to-FCF is 20.52. Zoetis' value of 17.14 is 16.5% below this benchmark. Historically, Zoetis' own EV-to-FCF has ranged from 16.73 to 73.26 over the past decade. While the company's 10-year median is 50.18 vs. the industry median of 20.52, Zoetis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.52, based on 560 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zoetis's current EV-to-FCF of 17.14 is 16.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zoetis and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zoetis's current EV-to-FCF is 17.14, which is 66% below median its own 10-year median of 50.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zoetis stock overvalued right now?
Based on GuruFocus' analysis, Zoetis (CHIX:ZOED) is currently considered Significantly Undervalued. The stock's GF Value™ is €179.46, compared to a current price of €66.44 — trading 63% below its estimated fair value. The current EV-to-FCF is 17.14, which is 66% below median its 10-year median of 50.18 and 16.5% below the Drug Manufacturers industry median of 20.52. Zoetis' overall GF Score™ is 65/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zoetis (CHIX:ZOED), the current EV-to-FCF is 17.14 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zoetis (CHIX:ZOED) Overvalued in 2026?
Based on GuruFocus' analysis, Zoetis stock appears to be undervalued.
The current stock price of €66.44 is trading 63% below its estimated GF Value™ of €179.46.
GuruFocus considers Zoetis to be Significantly Undervalued.
Key valuation signals for CHIX:ZOED:
EV-to-FCF: 17.14 (66% below median its 10-year median of 50.18)
GF Value™: €179.46 vs. price of €66.44 (63% below fair value)
Industry Position: 16.5% below the Drug Manufacturers median (#224 of 560)
No single metric tells the full story. See the CHIX:ZOED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
65GF Score
Get the complete analysis for CHIX:ZOED
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ZOED has been successfully added to your 
